市場調査レポート

商品コード

1293997

T細胞免疫療法市場：作用機序、製品クラス、治療タイプ、適応症別-2023-2030年の世界予測

T-Cell Immunotherapy Market by Mechanism Of Action, Product Class, Type of Therapy, Indication - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 744,453円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 901,213円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,973円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,371,493円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

T細胞免疫療法の世界市場は、2023年に59億8,433万米ドル、CAGR12.93％で大きく成長し、2030年には140億4,763万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のT細胞免疫療法市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.T細胞免疫療法の世界市場規模および予測は？

2.予測期間中、世界のT細胞免疫療法市場を形成するCOVID-19の阻害要因と影響は？

3.T細胞免疫療法の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.T細胞免疫療法の世界市場における競争戦略は？

5.T細胞免疫療法の世界市場における技術動向と規制の枠組みは？

6.T細胞免疫療法の世界市場における主要ベンダーの市場シェアは？

7.T細胞免疫療法の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - がんと自己免疫疾患の有病率の増加
  - 細胞ベースの標的療法の使用
  - T細胞免疫療法をサポートする研究開発の増加
- 抑制要因
  - 高額な治療費
- 機会
  - 製薬会社別商品化と資金提供
  - 既製療法の魅力
- 課題
  - 神経毒性とサイトカイン放出症候群
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章 T細胞免疫療法市場作用機序別

能動免疫療法
受動免疫療法

第7章 T細胞免疫療法市場製品クラス別

二重特異性抗体
サイトカイン
モノクローナル抗体
腫瘍溶解性ウイルス療法

第8章 T細胞免疫療法市場治療の種類別

CAR-T
TCR
TIL

第9章 T細胞免疫療法市場適応症別

B細胞悪性腫瘍
肝臓がん
前立腺がん
腎細胞がん

第10章南北アメリカのT細胞免疫療法市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域のT細胞免疫療法市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカのT細胞免疫療法市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第14章掲載企業一覧

第15章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. T-CELL IMMUNOTHERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2030 (%)
FIGURE 5. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2022 VS 2030 (%)
FIGURE 6. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2022 VS 2030 (%)
FIGURE 7. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 8. T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 9. T-CELL IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 10. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 19. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 5. T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 6. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 8. T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 13. T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 35. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 36. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 37. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 40. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 41. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 57. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 58. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 59. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 62. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 63. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 69. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 70. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 94. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 95. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 106. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 107. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 108. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 111. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 112. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 115. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 116. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 119. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 120. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 124. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 130. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 131. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 132. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 143. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 144. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 146. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 147. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 148. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 151. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 152. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 167. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 168. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 179. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 180. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 190. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 191. T-CELL IMMUNOTHERAPY MARKET LICENSE & PRICING

Product Code: MRR-034B5003094C

The Global T-Cell Immunotherapy Market is forecasted to grow significantly, with a projected USD 5,984.33 million in 2023 at a CAGR of 12.93% and expected to reach a staggering USD 14,047.63 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global T-Cell Immunotherapy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global T-Cell Immunotherapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Mechanism Of Action, market is studied across Active Immunotherapy and Passive Immunotherapy. The Passive Immunotherapy commanded largest market share of 68.62% in 2022, followed by Active Immunotherapy.

Based on Product Class, market is studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy. The Monoclonal Antibodies commanded largest market share of 40.71% in 2022, followed by Bispecific Antibodies.

Based on Type of Therapy, market is studied across CAR-T, TCR, and TIL. The TCR commanded largest market share of 33.90% in 2022, followed by TIL.

Based on Indication, market is studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma. The B-cell Malignancies commanded largest market share of 61.83% in 2022, followed by Liver Cancer.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 41.89% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global T-Cell Immunotherapy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global T-Cell Immunotherapy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Immunotherapy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Immunotherapy Market?

4. What is the competitive strategic window for opportunities in the Global T-Cell Immunotherapy Market?

5. What are the technology trends and regulatory frameworks in the Global T-Cell Immunotherapy Market?

6. What is the market share of the leading vendors in the Global T-Cell Immunotherapy Market?

7. What modes and strategic moves are considered suitable for entering the Global T-Cell Immunotherapy Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. T-Cell Immunotherapy Market, by Mechanism Of Action, 2022 vs 2030
4.3. T-Cell Immunotherapy Market, by Product Class, 2022 vs 2030
4.4. T-Cell Immunotherapy Market, by Type of Therapy, 2022 vs 2030
4.5. T-Cell Immunotherapy Market, by Indication, 2022 vs 2030
4.6. T-Cell Immunotherapy Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
  - 5.1.1.2. Use of Cell-Based Targeted Therapies
  - 5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
- 5.1.2. Restraints
  - 5.1.2.1. High Cost of Treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
  - 5.1.3.2. Attractiveness of Off-the-Shelf Therapies
- 5.1.4. Challenges
  - 5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. T-Cell Immunotherapy Market, by Mechanism Of Action

6.1. Introduction
6.2. Active Immunotherapy
6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class

7.1. Introduction
7.2. Bispecific Antibodies
7.3. Cytokines
7.4. Monoclonal Antibodies
7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy

8.1. Introduction
8.2. CAR-T
8.3. TCR
8.4. TIL

9. T-Cell Immunotherapy Market, by Indication

9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

T細胞免疫療法市場：作用機序、製品クラス、治療タイプ、適応症別-2023-2030年の世界予測

T-Cell Immunotherapy Market by Mechanism Of Action, Product Class, Type of Therapy, Indication - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 T細胞免疫療法市場作用機序別

第7章 T細胞免疫療法市場製品クラス別

第8章 T細胞免疫療法市場治療の種類別

第9章 T細胞免疫療法市場適応症別

第10章 南北アメリカのT細胞免疫療法市場

第11章 アジア太平洋地域のT細胞免疫療法市場

第12章 欧州・中東・アフリカのT細胞免疫療法市場

第13章 競合情勢

第14章 掲載企業一覧

第15章 付録

LIST OF FIGURES

LIST OF TABLES

Market Segmentation & Coverage:

This research report categorizes the Global T-Cell Immunotherapy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Market Statistics:

FPNV Positioning Matrix:

Market Share Analysis:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. T-Cell Immunotherapy Market, by Mechanism Of Action

7. T-Cell Immunotherapy Market, by Product Class

8. T-Cell Immunotherapy Market, by Type of Therapy

9. T-Cell Immunotherapy Market, by Indication

10. Americas T-Cell Immunotherapy Market

11. Asia-Pacific T-Cell Immunotherapy Market

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

13. Competitive Landscape

14. List of Company Mentioned

15. Appendix

1. Adaptimmune Therapeutics PLC

2. Apac Biotech

3. Atara Biotherapeutics, Inc.

4. Autolus Limited

5. bluebird bio, Inc.

6. Bristol-Myers Squibb Company

7. CARsgen Therapeutics, Ltd

8. Cellectis SA

9. Chimera Bioengineering

10. Dendreon Pharmaceuticals LLC

11. Eureka Therapeutics, Inc.

12. Gilead Sciences, Inc.

13. Green Cross Corporation

14. Innovative Cellular Therapeutics

15. Iovance Biotherapeutics, Inc.

16. JW CreaGene Co., Ltd.

17. LAVA Therapeutics BV

18. Lyell Immunopharma

19. Neogene Therapeutics

20. NeoTX Therapeutics

21. Novartis AG

22. Oxford Vacmedix

23. Poseida Therapeutics

24. TScan Therapeutics, Inc.

25. Xenetic Biosciences

26. ZIOPHARM Oncology

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要